<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283283</url>
  </required_header>
  <id_info>
    <org_study_id>A-13205</org_study_id>
    <nct_id>NCT00283283</nct_id>
  </id_info>
  <brief_title>Half vs Full Dose Influenza Vaccine</brief_title>
  <official_title>Clinical Study to Compare the Immune Response of Half Dose Trivalent Inactivated Influenza Vaccine (TIV) to Full Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Army Medical Materiel Development Activity</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uniformed Services University of the Health Sciences</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>U.S. Air Force Office of the Surgeon General</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared full-dose Flu vaccine to half-dose Flu-vaccine during the 2004-2005 flu
      season.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase II prospective, single-blind to dose, randomized study that compared the
      immunogenicity of subjects receiving half-dose Fluzone® compared to full-dose Fluzone®,
      2004-2005 formulation. 1440 healthy subjects, ages 18-64 years old and not currently
      indicated for influenza vaccination under the interim ACIP guidelines, were stratified by
      age, gender, and previous exposure to influenza vaccine, and randomized to receive either
      half-dose Fluzone® or full-dose Fluzone®.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response as measured by viral strain specific hemaggluttination inhibition (HAI) antibody levels</measure>
    <time_frame>Pre-vaccination and 21 days post-vaccincation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Medical events - upper respiratory illness and/or pneumonia</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Health care utilization and impact on productivity - number of days lost from work, hospitalizations, emergency room visits, unscheduled doctor's visits within 3-6 months following immunization</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">1316</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Male, Age 18 -49, Full Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male, Age 50 -64, Half Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female, Age 18 - 49, Full Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female, Age 18 - 49, Half Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male, Age 18 - 49, Half Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Male, Age 50 -64, Full Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female, Age 50 -64, Full Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female, Age 50 -64, Half Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone® (Aventis Pasteur inactivated influenza vaccine)</intervention_name>
    <description>A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002</description>
    <arm_group_label>Male, Age 18 -49, Full Dose</arm_group_label>
    <arm_group_label>Male, Age 50 -64, Half Dose</arm_group_label>
    <arm_group_label>Female, Age 18 - 49, Full Dose</arm_group_label>
    <arm_group_label>Female, Age 18 - 49, Half Dose</arm_group_label>
    <arm_group_label>Male, Age 18 - 49, Half Dose</arm_group_label>
    <arm_group_label>Male, Age 50 -64, Full Dose</arm_group_label>
    <arm_group_label>Female, Age 50 -64, Full Dose</arm_group_label>
    <arm_group_label>Female, Age 50 -64, Half Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Able to understand and comply with all study procedures including availability for
             all study visits and follow up surveys within 6 months following study enrollment.

               -  Age 18-49

                    -  Patients presenting to travel clinic with no exclusion criteria;

                    -  Household contacts and out-of-home caretakers of infants from 6-23 months of
                       age;

                    -  Hospital and/or employees providing service to the public who are not
                       eligible for the post-October 5th recommendations for priority immunization;

                    -  DOD employees eligible for influenza vaccination prior to October 5th but
                       excluded in the post October 5th guidelines;

                    -  People living in dormitories or under other crowded conditions, to prevent
                       outbreaks;

               -  Ages 50-64 years of age who are not eligible for the post-October 5th
                  recommendations for priority immunization and with no standard of care
                  contraindications to vaccination.

               -  Eligible in the Department of Defense for influenza vaccination

        Exclusion Criteria:

          -  • all children aged &lt; 18 years (includes children aged 6 months-18 years on chronic
             aspirin therapy);

               -  adults aged &gt;65 years;

               -  persons aged 2-64 years with underlying chronic medical conditions:

                    -  includes persons with chronic cardiac or pulmonary disease, diabetes
                       mellitus, hemoglobinopathy, or immunosuppressive illness;

                    -  any acute or chronic condition that, in the opinion of the investigator,
                       would render vaccination unsafe or interfere with the evaluation of
                       response.

               -  use of experimental vaccines or medications within 30 days of study entry;

               -  receipt of parenteral immunoglobulin within 60 days of study entry;

               -  all women who will be pregnant during the influenza season;

               -  residents of nursing homes and long-term care facilities;

               -  health-care workers involved in direct patient care and included in DOD priority
                  1; and;

               -  military recruits;

               -  out-of-home caregivers and household contacts of children aged &lt;6 months.

               -  Anyone with clinical contraindications for receiving the inactivated influenza
                  vaccine such as a history of severe allergic reaction to prior influenza
                  vaccinations, severe allergy to egg and/or egg proteins and gelatin.

               -  DOD Priority 1: Deployed or deploying (with orders) service members and others
                  designated as critical to national defense.

               -  DOD Priority 2: Medically high risk in accordance with ACIP guidelines (includes
                  health-care workers with direct patient contact)

               -  Any acute or chronic condition that, in the opinion of the investigator or her
                  provider designee would render vaccination unsafe or interfere with the
                  evaluation of the response.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renata J Engler, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pentagon</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, Klimov A, Keitel WA, Nichol KL, Carr WW, Treanor JJ; Walter Reed Health Care System Influenza Vaccine Consortium. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008 Dec 8;168(22):2405-14. doi: 10.1001/archinternmed.2008.513.</citation>
    <PMID>19064822</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2006</study_first_submitted>
  <study_first_submitted_qc>January 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <last_update_submitted>June 5, 2015</last_update_submitted>
  <last_update_submitted_qc>June 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 22, 2016</submitted>
    <returned>February 15, 2017</returned>
    <submitted>May 4, 2017</submitted>
    <returned>November 2, 2017</returned>
    <submitted>December 15, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

